Disease relevance of Carcinoma 256, Walker

• The effect of one single injection of two new bisphosphonates, 4-amino-1-hydroxybutylidene-1,1-bisphosphonate and 2-(2-pyridyl)ethylidene-1,1-bisphosphonate, and of dichloromethylenebisphosphonate on the hypercalcemia and hypercalciuria induced by the Walker carcinosarcoma 256/B in the thyroparathyroidectomized rat was evaluated [1].
• Rats with the solid Walker carcinosarcoma 256 were synchronized with hydroxyurea (6 x 50 mg/kg or 1 x 300 mg/kg body weight) and treated with bleomycin (32 mg/kg body weight) at different time points thereafter [2].
• Bone is a major source of transforming growth factor-beta (TGF-beta), and a preferred target organ for metastasis of the rat Walker carcinosarcoma 256 (W256) [3].
• In addition, alpha-carboline was assessed against i.p. inoculated plasmacytoma MP26 and colon carcinoma 26, and solid tumors of mammary carcinoma 16/C and Walker carcinosarcoma 256 [4].
• 1. Adenylosuccinate synthetase has been partially purified from rat liver, fetal rat liver, Novikoff ascites cells, Walker carcinoma 256 solid tumors, chicken liver and muscle, rabbit muscle and pig brain [5].

High impact information on Carcinoma 256, Walker

• Resistance patterns of Walker carcinosarcoma 256 and other rodent tumors to cyclophosphamide and L-phenylalanine mustard [6].
• Glucocorticoids decrease the production of parathyroid hormone-related protein in vitro but not in vivo in the Walker carcinosarcoma 256 rat model [7].
• Effects of diets deficient in glucose and glucose precursors on the growth of the Walker carcinosarcoma 256 in rats [8].
• The effects of carbohydrate-deficient diets on the growth of the Walker carcinosarcoma 256 in rats and on the carcinostatic action of the glucose analogue 2-deoxyglucose were studied [8].
• Three new nitrosoureas and chlorozotocin were screened for anticancer activity against Walker carcinoma 256 and DMBA-induced mammary cancer of the rat [9].

Chemical compound and disease context of Carcinoma 256, Walker

• Differences in pentobarbital disappearance rate in rats bearing two lines of Walker carcinosarcoma 256 [10].
• Therapy of solid Walker carcinosarcoma 256 with bleomycin after synchronization with hydroxyurea [2].
• Evidence of 1,25-dihydroxyvitamin D synthesis by the rat Walker carcinosarcoma 256 [11].
• ADM-OXD showed higher activity against Walker carcinosarcoma 256 than free adriamycin [12].
• Influence of dexamethasone and 1,25-Dihydroxyvitamin D on Walker carcinosarcoma 256 growth and parathyroid hormone-related protein secretion [13].

Anatomical context of Carcinoma 256, Walker

• 5-Chloro-2,3-dimethoxy-6-n-dodecylmercapto-1,4-benzoquinone (NSC 220334) and 5-chloro-6-omega-cyclohexylhexylmercapto-2,3-dimethoxy-1,4-benzoquinone (NSC 238136) were also active against the K 562c cell line and showed cures against the Walker carcinosarcoma 256 in rats [14].

Gene context of Carcinoma 256, Walker

• Osteolytic activity of Walker carcinosarcoma 256 is due to parathyroid hormone-related protein (PTHrP) [15].
• In this paper we describe studies on the Walker carcinosarcoma 256, a rat mammary tumor which exhibits chemotactic responses to factors in the media of cultured resorbing bone and to a factor generated by proteolysis of the fifth component of serum complement (C5) [16].
• Establishment and characterization of cell lines from the Walker carcinoma 256 able to grow in suspension culture and deficient in thymidine kinase [17].

Analytical, diagnostic and therapeutic context of Carcinoma 256, Walker

• The paper presents the results of experiments in which the perfusion of Walker carcinoma 256 in rats was influenced by s.c. application of isoprenaline under conditions of 45 degrees C hyperthermia [18].

References